SGl-1252: A Novel Approach to Obesity and Diabetes Treatment ID: 2015-032

A groundbreaking discovery involving activin-like kinase inhibitors for effective obesity and diabetes management.

Technology Overview

This invention from Brigham Young University introduces a novel use of the small molecule SGl-1252, an activin-like kinase inhibitor, for treating obesity and related metabolic disorders such as pre-diabetes and type 2 diabetes mellitus. By targeting type 1 receptors like ACVR2B, ALK4, and ALK5, SGl-1252 inhibits TGF-beta signaling, which is crucial in the conversion of white adipocytes into thermogenic, energy-burning brown adipocytes. This process not only promotes weight loss but also addresses obesity-related health issues.

Key Advantages

• Targets the underlying mechanisms of obesity and diabetes at the molecular level
• Promotes the conversion of white fat cells into brown fat cells, enhancing the body's ability to burn energy
• Has potential to significantly improve health outcomes for individuals with obesity-related disorders
• Novel mechanism of action with no closely related prior art, indicating a unique approach to treatment

Problems Addressed

• Effective management of obesity and its related pathologies, including pre-diabetes and type 2 diabetes mellitus
• Overcomes limitations of current treatments that may not target the root cause of obesity and related metabolic disorders

Market Applications

• Pharmaceuticals for the treatment of obesity and diabetes
• Weight management programs incorporating new therapeutic agents
• Potential for development into a wide range of therapeutic products and dietary supplements

Additional Information

Technology ID: 2015-032
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025